NFKBIA and breast carcinoma: It has been shown that bortezomib inhibits proteasomal degradation of IκBα induced by cytokines (i.e., TNFα) (29); however, IκBα was downregulated in both cell lines by bortezomib treatment, associated with enhanced phosphorylation in breast cancer cells.